Memantine 5 mg is marketed under the brand name Namenda [1][2].
What is Namenda prescribed for?
Namenda is prescribed to treat moderate to severe dementia of the Alzheimer's type [2][3]. It works by regulating the activity of glutamate, a neurotransmitter involved in learning and memory, which may help to slow down the cognitive decline associated with Alzheimer's disease [3].
How does Namenda work?
Namenda is an NMDA receptor antagonist. It works by blocking the effects of excess glutamate in the brain. In Alzheimer's disease, overstimulation by glutamate can lead to nerve cell damage and death. By blocking these overstimulatory effects, memantine aims to protect brain cells and improve cognitive function [3].
What are the different strengths of Namenda available?
Namenda is available in various dosage strengths, including 5 mg, 10 mg, and 15 mg tablets, as well as an oral solution [1][2]. The 5 mg dosage is typically used as a starting point for treatment, with dosages gradually increased as tolerated [2].
When does the patent for Namenda expire?
The original patents for memantine have expired, allowing for the introduction of generic versions [4]. DrugPatentWatch.com tracks patent information and exclusivity periods for medications like memantine [4].
Are there generic versions of Namenda available?
Yes, generic versions of memantine are available. The availability of generics typically follows the expiration of brand-name drug patents, which can lead to lower medication costs [4].
What are the common side effects of Namenda?
Common side effects associated with Namenda include dizziness, headache, confusion, constipation, and drowsiness [2]. It is important for patients to discuss any side effects with their healthcare provider.
Can Namenda be used in combination with other Alzheimer's medications?
Namenda can be used alone or in combination with other Alzheimer's medications, such as cholinesterase inhibitors, to manage symptoms [2][3].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.namenda.com/
3. https://www.medicinenet.com/memantine/article
4. https://www.drugpatentwatch.com/blog/alzheimers-drug-patent-expirations-and-generic-competition